High expression of IMPACT protein promotes resistance to indoleamine 2,3-dioxygenase-induced cell death

Journal of Cellular Physiology

Volumn 225, Issue 1, 2010, Pages 196-205

  Habibi, Darya ^a   Jalili, Reza B ^a   Forouzandeh, Farshad ^a   Ong, Christopher J ^a   Ghahary, Aziz ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENERAL CONTROL NONDEPRESSIBLE 2 KINASE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PROTEIN IMPACT; PROTEIN KINASE; REGULATOR PROTEIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRESS; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; KERATINOCYTE; LEUKEMIA CELL LINE; METABOLITE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CELL; T LYMPHOCYTE;

ANIMALS; ANTIVIRAL AGENTS; CELL DEATH; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; FIBROBLASTS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; JURKAT CELLS; KERATINOCYTES; KYNURENINE; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION FACTOR CHOP; TRYPTOPHAN;

EID: 77956552681     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22220     Document Type: Article

References (45)

1. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, Trucco M. 2002. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51:356-365.
2. Anthony TG, McDaniel BJ, Byerley RL, McGrath BC, Cavener DR, McNurlan MA, Wek RC. 2004. Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2. J Biol Chem 279:36553-36561.
3. Beutelspacher SC, Pillai R, Watson MP, Tan PH, Tsang J, McClure MO, George AJ, Larkin DF. 2006. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 36:690-700.
4. Bittencourt S, Pereira CM, Avedissian M, Delamano A, Mello LE, Castilho BA. 2008. Distribution of the protein IMPACT, an inhibitor of GCN2, in the mouse, rat, and marmoset brain. J Comp Neurol 507:1811-1830. (Pubitemid 351468225)
5. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. 1991. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 294:425-435.
6. Burke F, Knowles RG, East N, Balkwill FR. 1995. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer 60:115-122.
7. Crosby JS, Chefalo PJ, Yeh I, Ying S, London IM, Leboulch P, Chen JJ. 2000. Regulation of hemoglobin synthesis and proliferation of differentiating erythroid cells by heme-regulated eIF-2alpha kinase. Blood 96:3241-3248.
8. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P. 2006. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752-6761.
9. Forouzandeh F, Jalili RB, Germain M, Duronio V, Ghahary A. 2008a. Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4+ and CD8+ T cells. Mol Cell Biochem 309:1-7.
10. Forouzandeh F, Jalili RB, Germain M, Duronio V, Ghahary A. 2008b. Skin cells, but not T cells, are resistant to indoleamine 2, 3-dioxygenase (IDO) expressed by allogeneic fibroblasts. Wound Repair Regen 16:379-387.
11. Ghahary A, Li Y, Tredget EE, Kilani RT, Iwashina T, Karami A, Lin X. 2004. Expression of indoleamine 2,3-dioxygenase in dermal fibroblasts functions as a local immunosuppressive factor. J Invest Dermatol 122:953-964. (Pubitemid 38580998)
12. Ghahary A, Marcoux Y, Karimi-Busheri F, Li Y, Tredget EE, Kilani RT, Lam E, Weinfeld M. 2005. Differentiated keratinocyte-releasable stratifin (14-3-3 sigma) stimulates MMP-1 expression in dermal fibroblasts. J Invest Dermatol 124:170-177.
13. Hagiwara Y, Hirai M, Nishiyama K, Kanazawa I, Ueda T, Sakaki Y, Ito T. 1997. Screening for imprinted genes by allelic message display: Identification of a paternally expressed gene impact on mouse chromosome 18. Proc Natl Acad Sci USA 94:9249-9254.
14. Hainz U, Jurgens B, Heitger A. 2007. The role of indoleamine 2,3-dioxygenase in transplantation. Transpl Int 20:118-127.
15. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. 2000. Regulated translation initiation controls stress-induced gene expression inmammalian cells. Mol Cell 6:1099-1108.
16. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. 2000. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596-3599. (Pubitemid 30169812)
17. Jalili RB, Rayat GR, Rajotte RV, Ghahary A. 2007. Suppression of islet allogeneic immune response by indoleamine 2,3 dioxygenase-expressing fibroblasts. J Cell Physiol 213:137-143.
18. Jalili RB, Forouzandeh F, Moeenrezakhanlou A, Rayat GR, Rajotte RV, Uludag H, Ghahary A. 2009. Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol 174:196-205.
19. King NJ, Thomas SR. 2007. Molecules in focus: Indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 39:2167-2172.
20. Li Y, Tredget EE, Ghahary A. 2004. Cell surface expression of MHC class I antigen is suppressed in indoleamine 2,3-dioxygenase genetically modified keratinocytes: Implications in allogeneic skin substitute engraftment. Hum Immunol 65:114-123.
21. Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT, Ghahary A. 2006. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 126:128-136. (Pubitemid 43336104)
22. Li J, Meinhardt A, Roehrich ME, Golshayan D, Dudler J, Pagnotta M, Trucco M, Vassalli G. 2007. Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 293:H3415-H3423. (Pubitemid 350230883)
23. Liu H, Liu L, Fletcher BS, Visner GA. 2006. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med 173:566-572.
24. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. 2002. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295:868-872.
25. Mellor AL, Chandler P, Lee GK, Johnson T, Keskin DB, Lee J, Munn DH. 2002. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol 57:143-150.
26. Muller AJ, Prendergast GC. 2007. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 7:31-40.
27. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312-319. (Pubitemid 40460560)
28. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193.
29. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363-1372.
30. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280-290.
31. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22:633-642. (Pubitemid 40719198)
32. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
33. Okamura K, Sakaki Y, Ito T. 2005. Comparative genomics approach toward critical determinants for the imprinting of an evolutionarily conserved gene IMPACT. Biochem Biophys Res Commun 329:824-830.
34. Peacock JW, Palmer J, Fink D, Ip S, Pietras EM, Mui AL, Chung SW, Gleave ME, Cox ME, Parsons R, Peter ME, Ong CJ. 2009. PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Mol Cell Biol 29:1222-1234.
35. Pereira CM, Sattlegger E, Jiang HY, Longo BM, Jaqueta CB, Hinnebusch AG, Wek RC, Mello LE, Castilho BA. 2005. IMPACT, a protein preferentially expressed in the mouse brain, binds GCN1 and inhibits GCN2 activation. J Biol Chem 280:28316-28323.
36. Sarkhosh K, Tredget EE, Karami A, Uludag H, Iwashina T, Kilani RT, Ghahary A. 2003a. Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG). J Cell Biochem 90:206-217.
37. Sarkhosh K, Tredget EE, Li Y, Kilani RT, Uludag H, Ghahary A. 2003b. Proliferation of peripheral blood mononuclear cells is suppressed by the indoleamine 2,3-dioxygenase expression of interferon-gamma-treated skin cells in a co-culture system. Wound Repair Regen 11:337-345. (Pubitemid 37122565)
38. Sarkhosh K, Tredget EE, Uludag H, Kilani RT, Karami A, Li Y, Iwashina T, Ghahary A. 2004. Temperature-sensitive polymer-conjugated IFN-gamma induces the expression of IDO mRNA and activity by fibroblasts populated in collagen gel (FPCG). J Cell Physiol 201:146-154.
39. Takikawa O. 2005. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 338:12-19.
40. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. 1988. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263:2041-2048. (Pubitemid 18052167)
41. Taylor MW, Feng GS. 1991. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516-2522.
42. Todorovicc V, Chen CC, Hay N, Lau LF. 2005. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J Cell Biol 171:559-568.
43. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269-1274.
44. Varga J, Yufit T, Hitraya E, Brown RR. 1996. Control of extracellular matrix degradation by interferon-gamma. The tryptophan connection. Adv Exp Med Biol 398:143-148.
45. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873-9880.